UNLABELLED: Postmortem binding studies have established that the concentration of alpha(4)beta(2)-nicotinic acetylcholine receptors (alpha(4)beta(2)-nAChR) is reduced in advanced Alzheimer disease (AD). However, the status of this receptor in mild or prodromal AD has remained the subject of controversy. METHODS: We compared alpha(4)beta(2)-nAChR availability in 8 brain regions of living human subjects who had AD and mild cognitive impairment (MCI) with that in age-matched healthy control subjects by using the ligand (123)I-5-IA-85380 ((123)I-5-IA) and SPECT. All subjects (n = 32) were nonsmokers; they were administered (123)I-5-IA as a bolus plus a constant infusion and imaged 6-8 h later under equilibrium conditions. The effect of diagnosis on regional alpha(4)beta(2)-nAChR availability (regional brain activity/total parent concentration in plasma, proportional to the binding potential) was analyzed using multivariate analysis of covariance, controlling for the effects of age and sex. RESULTS: Despite a significant overall effect of diagnostic group on mean alpha(4)beta(2)-nAChR availability, univariate analyses revealed no group differences for any brain region analyzed. An exploratory analysis of the relationship between regional alpha(4)beta(2)-nAChR availability and neuropsychologic variables yielded several plausible correlations. However, after Bonferroni adjustment, only the correlation between the anterior cingulate and the Trail Making Test, Part B, in the healthy control subjects remained significant. CONCLUSION: These results are consistent with several postmortem and in vivo studies suggesting the preservation of nAChRs during the prodromal and early stages of AD. They support the interpretation that nAChR and other cholinergic reductions in AD are late-stage phenomena.
UNLABELLED: Postmortem binding studies have established that the concentration of alpha(4)beta(2)-nicotinic acetylcholine receptors (alpha(4)beta(2)-nAChR) is reduced in advanced Alzheimer disease (AD). However, the status of this receptor in mild or prodromal AD has remained the subject of controversy. METHODS: We compared alpha(4)beta(2)-nAChR availability in 8 brain regions of living human subjects who had AD and mild cognitive impairment (MCI) with that in age-matched healthy control subjects by using the ligand (123)I-5-IA-85380 ((123)I-5-IA) and SPECT. All subjects (n = 32) were nonsmokers; they were administered (123)I-5-IA as a bolus plus a constant infusion and imaged 6-8 h later under equilibrium conditions. The effect of diagnosis on regional alpha(4)beta(2)-nAChR availability (regional brain activity/total parent concentration in plasma, proportional to the binding potential) was analyzed using multivariate analysis of covariance, controlling for the effects of age and sex. RESULTS: Despite a significant overall effect of diagnostic group on mean alpha(4)beta(2)-nAChR availability, univariate analyses revealed no group differences for any brain region analyzed. An exploratory analysis of the relationship between regional alpha(4)beta(2)-nAChR availability and neuropsychologic variables yielded several plausible correlations. However, after Bonferroni adjustment, only the correlation between the anterior cingulate and the Trail Making Test, Part B, in the healthy control subjects remained significant. CONCLUSION: These results are consistent with several postmortem and in vivo studies suggesting the preservation of nAChRs during the prodromal and early stages of AD. They support the interpretation that nAChR and other cholinergic reductions in AD are late-stage phenomena.
Authors: Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff Journal: Acta Neuropathol Date: 2011-11-19 Impact factor: 17.088
Authors: Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-11 Impact factor: 9.236
Authors: A T Hillmer; I Esterlis; J D Gallezot; F Bois; M Q Zheng; N Nabulsi; S F Lin; R L Papke; Y Huang; O Sabri; R E Carson; K P Cosgrove Journal: Neuroimage Date: 2016-07-15 Impact factor: 6.556
Authors: Ioannis Ugo Isaias; Jörg Spiegel; Joachim Brumberg; Kelly P Cosgrove; Giorgio Marotta; Naoya Oishi; Takahiro Higuchi; Sebastian Küsters; Markus Schiller; Ulrich Dillmann; Christopher H van Dyck; Andreas Buck; Ken Herrmann; Susanne Schloegl; Jens Volkmann; Michael Lassmann; Klaus Fassbender; Reinhard Lorenz; Samuel Samnick Journal: Front Aging Neurosci Date: 2014-08-14 Impact factor: 5.750